@article{ed0acdce12ee45c6898293acade892d6,
title = "The Vulnerability Index: A weighted measure of dementia and cognitive impairment risk",
abstract = "Introduction: A brief, easily calculated and interpretable index to assess vulnerability to developing cognitive impairment is needed in clinical practice and research. To address this, we developed the Vulnerability Index (VI) with the goal of identifying individuals possessing a high risk for cognitive impairment. Methods: Twelve easily obtained sociodemographic, medical, and functional factors were used to develop the VI, with each selectively weighted based on factor analysis and predictive modeling. This cross-sectional study examined 387 subject-partner dyads. Results: The VI was found to accurately discriminate between cognitively normal controls and participants with cognitive impairment (area under the curve [AUC]: 0.844; 95% confidence interval [CI]: 0.776-0.913) and individuals scoring high on the VI (≥8) had worse health, functional, behavioral, cognitive, and quality of life ratings than those with lower scores. Discussion: The VI could be used in screening asymptomatic individuals for risk of cognitive impairment and guiding the development of primary and secondary prevention plans.",
keywords = "Alzheimer's disease, cognitive impairment, dementia, functional assessments, health records, primary prevention, risk assessment, screening, sociodemographics",
author = "Kleiman, {Michael J.} and Galvin, {James E.}",
note = "Funding Information: This study was supported by grants to JEG from the National Institute on Aging (R01 AG071514, R01 AG069765, and R01 NS101483), the Harry T. Mangurian Foundation, and the Leo and Anne Albert Charitable Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding Information: JEG is supported by grants from the National Institutes of Health (R01 AG071514, R01 AG069765, and R01 NS101483), Harry T. Mangurian Foundation, and Leo and Anne Albert Charitable Trust. All payments made to University of Miami Miller School of Medicine. JEG is the creator of the Quick Dementia Rating System (QDRS) – the copyright is held by New York University. The QDRS has been licensed by NYU to Biogen. Payments were made to the institution, and a portion is distributed to JEG. JEG has served as a consultant to Medivante‐Prophase, Biogen, and Premier. Payments were made to JEG. In conjunction with the University of Miami, JEG is patenting a Brain health platform. The patent is pending. JEG serves on 4 DSMB (Independent Data Monitoring Committee for PBFT02‐001 to Address Progranulin Mutations in Frontotemporal Degeneration. Sponsor: Passage Bio 2021‐present; Role: Voting member IDMC; A Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Safety and Efficacy of T3D‐959 in Subjects with Mild‐to‐Moderate Alzheimer's Disease. Sponsor: National Institute on Aging 2019‐present; Role: Chair DSMB; A Phase 1a, Double‐Blind, Randomized, Placebo‐Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of MW151 Administered Orally to Healthy Volunteers. Sponsor: National Institute on Aging 2019‐present; Role: Chair DSMB; Phase Ia, Randomized, Placebo‐controlled, Single and Multiple Dose, Dose‐Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNI‐362 in Healthy Aged Volunteers 50 to 72 Years of Age. Sponsor, National Institute on Aging 2018‐presnt. Role: Chair, DSMB). Payments are made to JEG for participation. JEG serves on the Board of Directors for the Lewy Body Dementia Association, the Lewy Body Dementia Resource Center, the South Florida Chapter of the Alzheimer's Association, and the South Palm Beach County YMCA. All positions are unpaid. Publisher Copyright: {\textcopyright} 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association",
year = "2021",
doi = "10.1002/dad2.12249",
language = "English (US)",
volume = "13",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",
number = "1",
}
